Scala Biodesign, a company specializing in protein design, has raised $16.0 million in new funding. This investment round will support the company's mission to revolutionize how proteins are developed across various industries.
Scala Biodesign stands at the forefront of protein design with its no-code one-shot software. This technology enables research and development teams to design complex proteins within a single design cycle, significantly increasing success rates, reducing R&D effort, and accelerating time-to-market for new bio-based products. The company's foundational technologies were developed by its founding team at the Weizmann Institute of Science, backed by an extensive record of over 130 peer-reviewed publications and collaborations with 80 commercial and academic partners. Notable achievements include the first-ever one-shot design of a malaria vaccine candidate, which is now progressing through Phase II clinical trials, and the successful design of proteins previously considered challenging across biotherapeutics, enzymes for biomanufacturing, and diagnostics.
The newly secured capital is intended to fuel Scala Biodesign's growth initiatives, including expanding its technological capabilities and market presence. Scala has already established partnerships with five of the top-20 pharmaceutical companies and other market leaders across multiple verticals, demonstrating the broad applicability and impact of its platform. By democratizing protein development, Scala aims to disrupt the field and enable more efficient creation of essential bio-based products.
Looking ahead, Scala Biodesign plans to utilize this funding to further scale its operations, enhance its software platform, and extend its reach within the biotechnology sector, driving continued innovation in protein engineering.
